Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06372496

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

GSK Investigational Site, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Has a diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2023 guidelines for at least 3 months prior to randomization.
  • Participants who are either:
  • Currently untreated
  • Treated with daily maintenance ICS or ICS/LABA
  • ACQ-6 score ≥1.5 at randomization.
  • Participants able to perform technically acceptable and repeatable FEV1 maneuvers (i.e., a minimum of 2 acceptable and 1 repeatable effort) at visit 2 (V2)
  • Participants must be able to complete the study questionnaires.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

  • Recent history of life-threatening asthma
  • History of >1 severe exacerbation of asthma within 12 months prior to randomization.
  • Women of childbearing potential that are not following at least one highly effective method of contraception. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • A WOCBP must have a negative pregnancy test ≤7 days prior to randomization.
  • Exposure to inhaler triple therapy [ICS + Long-acting muscarinic antagonist (LAMA) + LABA as Single inhaler triple therapy (SITT) or Multiple inhaler triple therapy(MITT)] and/or any LAMA-containing therapy within 12 months prior to randomization.
  • Ongoing need for biologic therapy or recent use of a biologic therapy
  • Participants with the diagnosis of chronic obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung Disease (GOLD 2024) guidelines.
  • Participants whose current medications include RELVAR ELLIPTA and ARNUITY ELLIPTA are not eligible to enter the study.
  • Participants who are medically unable to withhold their albuterol/salbutamol for 6 hours prior to spirometry testing
  • Changes in asthma medication (e.g., maintenance ICS/LABA) within 3 months prior to randomization.
  • Participants with a history of hypersensitivity to any of the study medications

Treatment and study plan

Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Drug

Participants will receive FF/UMEC/VI

Inhaled corticosteroids/long-acting beta-2 agonists

Drug

Participants will receive ICS/LABA

Primary outcomes

  1. Change from baseline in trough forced expiratory volume in 1 second (FEV1)

    Time frame: Baseline (Day 1), and at Week 24

Secondary outcomes

  1. Number of participants achieving ≥0.5 point improvement from baseline for the Asthma Control Questionnaire-7 (ACQ-7) after 24 weeks of treatment

    Time frame: Baseline (Day 1), and Week 24

    The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation).Higher scores indicate greater impairment. ACQ-7 is the responder analysis based on a 0.5 point change.

  2. Number of participants achieving the composite endpoint (optimized) after 52 weeks of treatment

    Time frame: Up to 52 weeks

    The 4-point composite endpoint is defined as meeting the following criteria:

    • Change from baseline in trough FEV1 ≥ 100 mL at Week 52.
    • Controlled asthma based on ACQ-5 total score ≤ 1.5 at Week 52.
    • No severe asthma exacerbations over 52 weeks.
    • OCS-free over 52 weeks

  3. Change from baseline in trough forced expiratory volume in 1 second (FEV1) after 52 weeks of treatment

    Time frame: Baseline (Day 1), and Week 52

  4. Change from baseline in trough FEV1 ≥ 100mL after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

  5. Change from baseline in through FEV1 ≥ 0mL after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

  6. Number of participants achieving ≥0.5 point improvement from baseline for the ACQ-7 after 52 weeks of treatment

    Time frame: Week 52

    The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment. ACQ-7 is the responder analysis based on a 0.5 point change.

  7. Number of participants achieving ≥0.5 point improvement from baseline for the Asthma Control Questionnaire-6 (ACQ-6) after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-6 is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. The scoring ranges from 0 (no impairment/ limitation) to 6 (total impairment/ limitation), higher scores indicate greater impairment. ACQ-6 is the responder analysis based on a 0.5 point change.

  8. Number of participants achieving ≥0.5 point improvement from baseline for the ACQ-5 after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-5 consists of 5 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. It is a shorter version of ACQ-7 derived by removal of two elements (lung function and rescue use elements) from original version (ACQ-7). ACQ-5 is the responder analysis based on a 0.5 point change.

  9. Change from baseline in the ACQ-7 total score after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-7 total consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment.

  10. Change from baseline in the ACQ-5 total score after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-5 total consists of 5 questions scored from zero (no impairment/limitation) to six (total impairment/ limitation). Higher scores indicate greater impairment. It is a shorter version of ACQ-7 derived by removal of two elements (lung function and rescue use elements) from original version (ACQ-7).

  11. Change from baseline in the ACQ-6 total score after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-6 total is a shortened version of the ACQ-7 derived by removing one element (lung function element) from the original version. The scoring ranges from 0 (no impairment/limitation) to 6 (total impairment/ limitation), higher scores indicate greater impairment.

  12. Change from baseline in the Asthma Control Test (ACT) score after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACT is a 5-question health survey used to measure asthma control in participants aged ≥12 years. Each question is scored from 1 to 5 for a total score ranging from 5 to 25; with higher scores indicating better asthma control.

  13. Number of participants achieving the composite endpoint among those on ICS/LABA prior to randomization

    Time frame: Week 52

    The 4-point composite endpoint is defined as meeting the following criteria:

    • Change from baseline in trough FEV1 ≥ 100 mL at Week 52
    • Controlled asthma based on ACQ-5 total score ≤ 1.5 at Week 52
    • No severe asthma exacerbations over 52 weeks
    • OCS-free over 52 weeks

  14. Number of participants achieving the composite endpoint among those on no treatment prior to randomization

    Time frame: Up to 52 weeks

    The 4-point composite endpoint is defined as meeting the following criteria:

    • Change from baseline in trough FEV1 ≥ 100 mL at Week 52.
    • Controlled asthma based on ACQ-5 total score ≤ 1.5 at Week 52.
    • No severe asthma exacerbations over 52 weeks.
    • OCS-free over 52 weeks

  15. Change from baseline in the Asthma Quality of Life Questionnaire (AQLQ-12) total scores after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The AQLQ (+12), is a modified version of the original AQLQ with standardized activities. The response scale ranges from 1 (totally impaired) to 7 (not at all impaired). The total score is the score from all 32 questions.

  16. Change from baseline in the Asthma Quality of Life Questionnaire (AQLQ-12) domain scores after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The AQLQ (+12), is a modified version of the original AQLQ with standardized activities. The response scale ranges from 1 (totally impaired) to 7 (not at all impaired). The domain score looks at each domain individually - symptoms, activity limitation, emotional function and environmental stimuli.

  17. Change from baseline in the four domains of the asthma-specific adaptation of the Work Productivity and Activity Impairment Questionnaire (WPAI:Asthma) after 24 and 52 weeks of treatment

    Time frame: Baseline (Day 1), Week 24 and Week 52

    WPAI is a self-administered tool to determine the degree to which asthma affected work productivity while at work and affected activities outside of work in the last 7 days. The WPAI questionnaire score represents the percentage of impairment, from 0 to 100%. Higher WPAI scores indicate greater activity impairment.

  18. Change from baseline in trough forced expiratory volume in 1 second (FEV1) among participants on budesonide/formoterol prior to randomization

    Time frame: Baseline (Day 1), and Week 24

  19. Number of participants achieving ≥0.5 points improvement from baseline for ACQ-7 among participants on ICS/LABA prior to randomization

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment. ACQ-7 is the responder analysis based on a 0.5 point change.

  20. Change from baseline in the ACQ-7 total score among participants on ICS/LABA prior to randomization

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-7 total consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment.

  21. Change from baseline in trough forced expiratory volume in 1 second (FEV1) for participants with no treatment prior to randomization.

    Time frame: Baseline (Day 1), and Week 24

  22. Number of participants achieving ≥0.5 points improvement from baseline for ACQ-7 for participants with no treatment prior to randomization.

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-7 consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment. ACQ-7 is the responder analysis based on a 0.5 point change.

  23. Change from baseline in the ACQ-7 total score for participants with no treatment prior to randomization.

    Time frame: Baseline (Day 1), Week 24 and Week 52

    The ACQ-7 total consists of 7 questions scored between zero (no impairment/ limitation) to 6 (total impairment/ limitation). Higher scores indicate greater impairment. s

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

Acronym: PERFORM

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
Apr 18, 2024
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.